Jui Choudhuri

Dr. Jui Choudhuri

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJui Choudhuri
Jui Choudhuri
JCJamal Carter
Jamal Carter
RNRandin Nelson
Randin Nelson
KSKarin Skalina
Karin Skalina
MOMarika Osterbur-Badhey
Marika Osterbur-Badhey
JSJames Szymanski
James Szymanski
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The utility of cycle threshold, at admission, as a predictor of disease severity has not been thoroughly investigated.Methods and findings: We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n = 1044). Only patients with complete survival data, discharged (n = 774) or died in hospital (n = 270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD = 5.8) compared to non-survivors (24.8, SD = 6.0, P<0.001). In-hospital mortality significantly differed (p<0.05) by Ct quartile. After adjusting for age, gender, BMI, hypertension and diabetes, increased cycle threshold was associated with decreased odds of in-hospital mortality (0.91, CI 0.89–0.94, p<0.001). Compared to the 4thQuartile, patients with Ct values in the 1st Quartile (Ct <22.9) and 2nd Quartile (Ct 23.0–27.3) had an adjusted odds ratio of in-hospital mortality of 3.8 and 2.6 respectively (p<0.001). The discriminative ability of Ct to predict inpatient mortality was found to be limited, possessing an area under the curve (AUC) of 0.68 (CI 0.63–0.71).Conclusion: SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test.

20 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JCJui Choudhuri
Jui Choudhuri
JCJamal Carter
Jamal Carter
RNRandin Nelson
Randin Nelson
KSKarin Skalina
Karin Skalina
MOMarika Osterbur-Badhey
Marika Osterbur-Badhey
JSJames Szymanski
James Szymanski
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The relationship of initial Ct at hospitalization and patient mortality has not been thoroughly investigated. Methods and findings: We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n=1044). Only patients with complete survival data discharged (n=774) or died in hospital (n=270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD=5.8) compared to non-survivors (24.8, SD=6.0, P<0.001). Patients with lower Ct value on admission had higher odds ratio (0.91, CI 0.89-0.94, p32.9) had lower odds of in-hospital death (P<0.001). On comparing, Ct quartiles, mortality, BMI and GFR were significantly different (p<0.05) between the groups. The cumulative incidence of all-cause mortality and discharge was found to differ between Ct quartiles (Gray’s Test P<0.001). Conclusion: SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test. AUTHOR SUMMARY: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has effected the entire world, with approximately 23 million affected till date. Clinicians, researcher and scientists are making all efforts to identify ways of diagnosis, predicting outcome and treatment modalities. The polymerase chain reaction (rT-PCR) technology, is the standard test being used for the diagnosis and it gives an additional value known as “cycle threshold” (Ct), which is the number of PCR cycles required to cross the designated threshold and termed patient as positive for the infection. This Ct value is inverse of the viral load in the patient and has been studied as indicator of outcome of infection. In this study we have analyzed the Ct value as a predictor for mortality and compared it between different age and gender. We found the Ct value significantly different between those who survived and those who died due to the disease. However proper utilization of the Ct value needs further studies to be utilized in the clinical setting and guide decision making.

2 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JCJiani N. Chai
Jiani N. Chai
JCJui Choudhuri
Jui Choudhuri
JGJerald Z. Gong
Jerald Z. Gong
YWYanhua Wang
Yanhua Wang
XTXuejun Tian
Xuejun Tian
EZH2, a subunit of the polycomb repressive complex 2 (PRC2), is an important methyltransferase that catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3). EZH2 is overexpressed in various malignancies. Here, we investigated EZH2 expression and potential signaling molecules that correlate with EZH2 expression in ATLL and other T-cell neoplasms. Immunohistochemical staining (IHC) was performed for EZH2, pERK, MYC, and pSTAT3 on 43 ATLL cases and 104 cases of other T-cell neoplasms. Further IHC studies were conducted for Ki-67, SUZ12, and H3K27me3 on ATLL cases. All ATLL cases showed EZH2 overexpression. In other T-cell neoplasms, a high prevalence of EZH2 overexpression was identified (86%), except for T-PLL (33%). In ATLL, EZH2 overexpression correlated with pERK co-expression (86%), while only a small subset of cases showed MYC (7%) or pSTAT3 (14%) co-expression. In the other T-cell neoplasms, there was a variable, but higher, co-expression of EZH2 with pERK, MYC, and pSTAT3. In ATLL, enhanced EZH2 expression correlated with higher Ki-67 staining, SUZ12 (another PRC2 subunit), and H3K27me3 co-expression. In conclusion, EZH2 is overexpressed in ATLL and is associated with pERK expression. It correlates with an increased proliferation index, indicating an aggressive clinical course. EZH2 also correlates with SUZ12 and H3K27me3 co-expression, suggesting its PRC2-dependent catalytic activity through trimethylation. Additionally, EZH2 is overexpressed in most T-cell neoplasms, suggesting that EZH2 could function as an oncogenic protein in T-cell tumorigenesis. EZH2 and pERK could serve as potential therapeutic targets for treating aggressive ATLL. EZH2 could also be targeted in other T-cell neoplasms.

30 October 2020 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
JCJui Choudhuri
Jui Choudhuri
LRLeah Geiser Roberts
Leah Geiser Roberts
YZYan Zhang
Yan Zhang
YWYanhua Wang
Yanhua Wang
YFYanan Fang
Yanan Fang
Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell neoplasm caused by infection of the human T-cell lymphotropic virus type 1 (HTLV-1). Most ATLL cases are CD4-positive and CD8-negative. Though rare, there are a few dual negative (CD4−CD8−), dual positive (CD4+CD8+), and CD4−CD8+ cases reported in literature. ATLL is associated with HTLV-1 infection, but HTLV-1 alone cannot cause the malignant transformation of infected T cells. Additional genetic and/or epigenetic events are required for the development of the disease. Here, we report an unusual CD4−CD8+ATLL in a 76-year-old male with a unique molecular genetic profile. Molecular studies revealed alterations in 10 genes. Three of them are predicted to be pathogenic by the computational models, including the frameshift change in ZFHX4 and missense mutations in RHOA and POT1. The specific mutations of POT1 (c.281A > G; p.Q94R), RHOA (c.47G > A; p.C16Y), and ZFHX4 (c.2871delC; p.F958Sfs31) have never been previously reported in ATLL to the best of our knowledge. The clinical significance of other genetic alterations is unknown. Further research is warranted to correlate this patient’s molecular findings with other ATLL cases. Correlation specifically with other cases of CD8+ ATLL could prove to be useful in understanding the pathogenesis of this rare variant of an already rare form of leukemia/lymphoma.

1 January 2020 in Indian Journal of Nephrology
Verified
Journal Article
Open access
CRChhavi Rajvanshi
Chhavi Rajvanshi
ATAseemKumar Tiwari
AseemKumar Tiwari
JCJui Choudhuri
Jui Choudhuri
SMSimmi Mehra
Simmi Mehra
RCRajni Chauhan
Rajni Chauhan
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

26 December 2023 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
KKKritika Krishnamurthy
Kritika Krishnamurthy
JCJui Choudhuri
Jui Choudhuri
KRK. H. Ramesh
K. H. Ramesh
YWYanhua Wang
Yanhua Wang
Acute promyelocytic leukemia (APL) is characterized by the pathogenic driver fusion transcript PML-RARA resulting from the t(15;17) translocation. Early recognition of APL with prompt ATRA induction has a decisive impact on the early death rate. The preliminary diagnosis of APL relies heavily on cytomorphology and flow cytometry. In APL with variant morphology, such as the microgranular variant, immunophenotype, especially the bright MPO positivity is the basis of diagnosis. Till date, only five cases of APL with reduced/absent MPO have been described in literature. The identification of MPO deficiency based on genetic testing would involve at the least a MPO gene scanning with NGS, followed by microarray to identify somatic uniparental disomy in heterozygotes. This testing is not only redundant given the scant clinical implications of heterozygous MPO deficiency but also time consuming. An easy way to identify background MPO deficiency confounding the immunophenotype of a myeloid neoplasm is the MPO expression in background neutrophils gated on the initial flow cytometry. A dim MPO in the background neutrophils, in the morphological setting of APL, can identify underlying MPO deficiency, clarifying the immunophenotypic ambiguity and thus establishing an unequivocal diagnosis as seen in the current case.